NCT04798586View on ClinicalTrials.gov

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 22, 2021

Primary Completion Date

May 27, 2022

Study Completion Date

May 17, 2023

Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
DRUG

Elranatamab (PF-06863135)

BCMA-CD3 bispecific antibody

Trial Locations (2)

467-8602

Nagoya City University Hospital, Nagoya

150-8935

Japanese Red Cross Medical Center, Shibuya-ku

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04798586 - MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma | Biotech Hunter | Biotech Hunter